主要投资者提高了在开发自发免疫疾病治疗的生物技术公司Argenx的股份。 Major investors boosted their stakes in biotech firm Argenx, which develops autoimmune disease treatments.

Allspring Global Investments Holdings LLC 在第一季度将其在 Argenx SE 的持股增加了 22.4%，目前拥有 176,450 股股票，价值约 1 亿美元。 Allspring Global Investments Holdings LLC increased its holdings in Argenx SE by 22.4% in the first quarter, now owning 176,450 shares worth about $100 million. J.Safra资产管理公司也将其Argenx持有的股份增加了71.4%,拥有468股,价值277 000美元。 J.Safra Asset Management Corp also raised its Argenx holdings by 71.4%, owning 468 shares worth $277,000. Argenx是一家生物技术公司,开发自发免疫性疾病的治疗方法,并拥有“Buy”评级,价格指标为729.93美元。 Argenx, a biotech firm, develops therapies for autoimmune diseases and has a "Buy" rating with a price target of $729.93.